Susan Mahony
CIK 1463321 · SVP & Pres., Lilly Oncology · last filed 2026-06-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$66.05M
Companies
5
Total Filings
64
Lifetime Open-Market Net
-$13.39M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AXSM | Director | 829 | $212.74 | $176.4K | -$145.0K | 7 | 2026-06-10 |
| ASMB | Director | — | $26.68 | — | $0 | 10 | 2026-06-05 |
| ZYME | Director | — | $23.54 | — | $0 | 6 | 2026-01-12 |
| Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Director | 0 | $116.30 | $0 | $0 | 7 | 2023-10-06 |
| LLY | SVP & Pres., Lilly Oncology | 55,559 | $1185.71 | $65.88M | -$13.25M | 32 | 2019-02-01 |
Recent Filings · Page 2 of 7
64 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-11 | AXSM | Grant (A) | — | $0 | EDGAR |
| 2024-05-30 | ASMB | Grant (A) | — | $0 | EDGAR |
| 2024-02-29 | AXSM | Grant (A) | — | $0 | EDGAR |
| 2023-12-08 | ZYME | Grant (A) | — | $0 | EDGAR |
| 2023-10-12 | AXSM | Grant (A) | — | $0 | EDGAR |
| 2023-10-06 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Disp (D) | −18,651 | -$2.17M | EDGAR |
| 2023-07-28 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-30 | ASMB | Grant (A) | — | $0 | EDGAR |
| 2023-05-02 | Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Mixed | +2,034 | -$208.9K | EDGAR |
| 2022-12-23 | ZYME | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.